NFKB1 and chronic kidney disease: However, another recent randomized placebo-controlled clinical trial in twenty-five CKD stage 3–5 patients [48] evaluated the effects of sulforaphane on the mRNA expression of Nrf2, NF-κβ, and markers of oxidative stress (lipid peroxidation and protein carbonylation).